Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (GB:0EE0)
LSE:0EE0
uniQure (0EE0) Share Price & Analysis
1 Followers
0EE0 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.74 - $10.86
Previous Close$8.71
Volume16.93K
Average Volume (3M)24.82K
Market Cap
$416.07M
Enterprise Value$310.11M
Total Cash (Recent Filing)$243.06M
Total Debt (Recent Filing)$137.10M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Jul 31, 2024EPS Estimate
-$1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,549,437
10 Day Avg. Volume215
30 Day Avg. Volume24,825
Standard Deviation0.23
R-Squared0.09
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)1.84
Price to Sales (P/S)210.13
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue16.32
Enterprise Value/Gross Profit140.00
Enterprise Value/Ebitda-1.33
Forecast
1Y Price Target
$21.57Price Target Upside147.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
uniQure News
PremiumCompany Announcements
uniQure Advances with Strategic Facility Sale and Partnership Deals
Bulls Say, Bears Say
Bulls Say
Biomarker ReductionPatients treated with AMT-130 had a significant reduction in CSF neurofilament light chain, showing a mean reduction of 11% at 24 months compared to baseline.
Clinical OutcomesAMT-130 demonstrated a statistically significant dose-dependent slowing in Huntington's disease progression at 24 months.
Cost ReductionThe sale of the AAV manufacturing facility to Genezen will reduce uniQure’s cash burn by approximately $40 million annually.
Bears Say
Financial PerformanceHemgenix license revenues remained modest.
Operational CostsThere is no other near-term commercial gene-therapy product to help generate cash needed to support the high operational costs of owning a gene-therapy manufacturing facility.
Regulatory ConcernsThe change in cUHDRS for patients treated with low-dose AMT-130 was not statistically significant compared to the external control arm at month 24.
---
Options Prices
Currently, No data available
---
Ownership Overview
4.39% Insiders
11.73% Mutual Funds
5.63% Other Institutional Investors
78.24% Public Companies and
Individual Investors
0EE0 FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest share price was $3.74 and its highest was $10.86 in the past 12 months.
What is uniQure N.V.’s market cap?
Currently, no data Available
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Jul 31, 2024 which is in 4 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on May 07, 2024. The company reported -$1.36 earnings per share for the quarter, missing the consensus estimate of -$1.279 by -$0.081.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -$1.25.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 48,549,440 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$1.36 in its last earnings report, missing expectations of -$1.279. Following the earnings report the stock price went up 2.144%.
Which hedge fund is a major shareholder of uniQure N.V.?
Among the largest hedge funds holding uniQure N.V.’s share is Bridger Management, LLC. It holds uniQure N.V.’s shares valued at 2M.
---
uniQure Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.57 (147.62% Upside)
$21.57 (147.62% Upside)
Blogger Sentiment
Bullish
GB:0EE0 Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $149.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.88%
12-Months-Change
Fundamentals
Return on Equity
-106.11%
Trailing 12-Months
Asset Growth
22.04%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
---
0EE0 Stock 12 Month Forecast
Average Price Target
$21.57
▲(147.62% Upside)
Technical Analysis
uniQure
―
Abeona Therapeutics
―
Adverum Biotechnologies
―
Alnylam Pharma
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering 0EE0
1 Year
1 Year Success Rate
10/22 ratings generated profit
1 Year Average Return
-20.17%
reiterated a buy rating 18 days ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -20.17% per trade.
---